[Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis].
The article provides the data on 20 patients with erosive reflux esophagitis, who were treated with Pariet (rabeprazole). It was shown on the basis of conducted clinical endoscopic, morphological and immunohistochemical studies that the application of Pariet in treatment of patients with erosive esophagitis contributes to clinical endoscopic remission, regression of inflammatory changes, recovery of apoptosis processes and proliferative activity of esophagus epithelial cells within a shorter period of time. The results of the observation allow recommending Pariet as a highly efficient preparation for treatment of patients with gastroesophageal reflux disease.
Osadchuk
M A
MA
State Medical University, Military-Medical Institute, Saratov.
Lipatova
T E
TE
Chaplygin
N V
NV
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002908:Chronic Disease; D004847:Epithelial Cells / Q000473:pathology; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000473:pathology; D004947:Esophagus / Q000187:drug effects / Q000473:pathology; D006801:Humans; D009092:Mucous Membrane / Q000187:drug effects / Q000473:pathology; D009853:Omeprazole / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D009853:Omeprazole